Physician profile
Eric Stewart
NPI 1801973870
$4,577.09
in general payments reported to CMS, 2019-2025
19 companies · $785 in 2025
The $785 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $378 · 2021: $371 · 2022: $880 · 2023: $639 · 2024: $961 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,282 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.15 |
| Education | $103.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,428.15 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $758.95 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $636.27 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $313.89 | 2019-2025 | |
| Genzyme Corporation | $288.87 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $266.27 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $209.59 | 2019-2025 | Ilumya |
| Ucb, INC. | $171.62 | 2020-2025 | Bimzelx |
| Organogenesis INC. | $94.01 | 2023-2024 | Affinity, Puraply |
| E.R. Squibb & Sons, L.L.C. | $79.84 | 2023-2024 | Sotyktu |
| Amgen INC. | $75.90 | 2020-2024 | Otezla |
| Genentech USA, INC. | $70.47 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $61.12 | 2019-2023 | Libtayo |
| Galderma Laboratories, L.P. | $33.87 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.66 | 2024 | Siliq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $21.05 | 2023 | Adbry |
| Kyowa Kirin, INC. | $16.74 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.10 | 2024 | Spevigo |
| Helsinn Therapeutics (U.S.), INC. | $12.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.